230 related articles for article (PubMed ID: 31276604)
1. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.
Sawada Y; Kikugawa T; Iio H; Sakakibara I; Yoshida S; Ikedo A; Yanagihara Y; Saeki N; Győrffy B; Kishida T; Okubo Y; Nakamura Y; Miyagi Y; Saika T; Imai Y
Int J Cancer; 2020 Mar; 146(5):1369-1382. PubMed ID: 31276604
[TBL] [Abstract][Full Text] [Related]
2. G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells.
Zhou C; Dai X; Chen Y; Shen Y; Lei S; Xiao T; Bartfai T; Ding J; Wang MW
Oncotarget; 2016 Mar; 7(11):12823-39. PubMed ID: 26871479
[TBL] [Abstract][Full Text] [Related]
3. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.
Dey P; Jonsson P; Hartman J; Williams C; Ström A; Gustafsson JÅ
Mol Endocrinol; 2012 Dec; 26(12):1991-2003. PubMed ID: 23028063
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.
Chen WY; Liu SY; Chang YS; Yin JJ; Yeh HL; Mouhieddine TH; Hadadeh O; Abou-Kheir W; Liu YN
Oncotarget; 2015 Jan; 6(1):441-57. PubMed ID: 25436980
[TBL] [Abstract][Full Text] [Related]
6. The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3β in Pancreatic Cancer.
Liu B; Yang H; Pilarsky C; Weber GF
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29949874
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
8. The role of S100A4 for bone metastasis in prostate cancer cells.
Kim B; Jung S; Kim H; Kwon JO; Song MK; Kim MK; Kim HJ; Kim HH
BMC Cancer; 2021 Feb; 21(1):137. PubMed ID: 33549040
[TBL] [Abstract][Full Text] [Related]
9. Elevation of GPRC5A expression in colorectal cancer promotes tumor progression through VNN-1 induced oxidative stress.
Zhang L; Li L; Gao G; Wei G; Zheng Y; Wang C; Gao N; Zhao Y; Deng J; Chen H; Sun J; Li D; Zhang X; Liu M
Int J Cancer; 2017 Jun; 140(12):2734-2747. PubMed ID: 28316092
[TBL] [Abstract][Full Text] [Related]
10. PKCε Is an Essential Mediator of Prostate Cancer Bone Metastasis.
Gutierrez-Uzquiza A; Lopez-Haber C; Jernigan DL; Fatatis A; Kazanietz MG
Mol Cancer Res; 2015 Sep; 13(9):1336-46. PubMed ID: 26023164
[TBL] [Abstract][Full Text] [Related]
11. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
[TBL] [Abstract][Full Text] [Related]
12. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
Fort RS; Mathó C; Geraldo MV; Ottati MC; Yamashita AS; Saito KC; Leite KRM; Méndez M; Maedo N; Méndez L; Garat B; Kimura ET; Sotelo-Silveira JR; Duhagon MA
BMC Cancer; 2018 Feb; 18(1):127. PubMed ID: 29394925
[TBL] [Abstract][Full Text] [Related]
13. GPRC5A overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer.
Liu H; Zhang Y; Hao X; Kong F; Li X; Yu J; Jia Y
Tumour Biol; 2016 Jan; 37(1):503-10. PubMed ID: 26227221
[TBL] [Abstract][Full Text] [Related]
14. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.
Feng S; Agoulnik IU; Truong A; Li Z; Creighton CJ; Kaftanovskaya EM; Pereira R; Han HD; Lopez-Berestein G; Klonisch T; Ittmann MM; Sood AK; Agoulnik AI
Endocr Relat Cancer; 2010 Dec; 17(4):1021-33. PubMed ID: 20861284
[TBL] [Abstract][Full Text] [Related]
15. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
[TBL] [Abstract][Full Text] [Related]
17. GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
Song H; Sun B; Liao Y; Xu D; Guo W; Wang T; Jing B; Hu M; Li K; Yao F; Deng J
Int J Cancer; 2019 Feb; 144(4):777-787. PubMed ID: 29992578
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.
Zoni E; Astrologo L; Ng CKY; Piscuoglio S; Melsen J; Grosjean J; Klima I; Chen L; Snaar-Jagalska EB; Flanagan K; van der Pluijm G; Kloen P; Cecchini MG; Kruithof-de Julio M; Thalmann GN
Mol Cancer Res; 2019 May; 17(5):1049-1062. PubMed ID: 30745464
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
